Ohev-Zion Michal Gilon Form 3 Anchiano Therapeutics / Ohev-Zion Michal Gilon ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gilon Ohev-Zion Michal

(Last)

(First)

(Middle)

C/O ANCHIANO THERAPEUTICS LTD.

5 KIRYAT HAMADA ST., P.O. BOX 45032

(Street)

JERUSALEM

9777401

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2020

3. Issuer Name and Ticker or Trading Symbol
Anchiano Therapeutics Ltd. [ ANCN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
VP, Research and Development

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee stock options	⁽¹⁾	03/06/2021	Ordinary Shares	236	67.03⁽²⁾	D
Employee stock options	⁽³⁾	03/06/2023	Ordinary Shares	1,766	23.91⁽⁴⁾	D
Employee stock options	⁽⁵⁾	05/10/2024	Ordinary Shares	2,252	6.79⁽⁶⁾	D
Employee stock options	⁽⁷⁾	04/28/2025	Ordinary Shares	3,000	3.13⁽⁸⁾	D
Employee stock options	⁽⁹⁾	09/09/2027	Ordinary Shares	40,000	2.6⁽¹⁰⁾	D
Employee stock options	⁽¹¹⁾	07/02/2029	Ordinary Shares	53,000	1.03	D

Explanation of Responses:

1. 1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on March 6, 2011.

2. The exercise price was converted from New Israeli Shekel ("NIS") 242.03 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

3. 1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on March 7, 2013.

4. The exercise price was converted from New Israeli Shekel ("NIS") 86.62 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

5. 1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on March 2, 2014.

6. The exercise price was converted from NIS 23.44 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

7. 1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on February 22, 2015.

8. The exercise price was converted from NIS 12.10 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

9. 1/4 of the options vest one year following the vesting commencement date of September 10, 2017, and 1/16 at the end of each calendar quarter thereafter, until fully vested.

10. The exercise price was converted from NIS 9.10 using the closing rate of exchange of the Bank of Israel on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

11. 1/16 of the options vest at the end of each calendar quarter until fully vested, beginning on May 21, 2019.

	/s/ Michal Gilon	01/02/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Ohev-Zion Michal Gilon Form 3Anchiano Therapeutics / Ohev-Zion Michal Gilon ownership change